AU2002309583A1 - Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer - Google Patents

Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer

Info

Publication number
AU2002309583A1
AU2002309583A1 AU2002309583A AU2002309583A AU2002309583A1 AU 2002309583 A1 AU2002309583 A1 AU 2002309583A1 AU 2002309583 A AU2002309583 A AU 2002309583A AU 2002309583 A AU2002309583 A AU 2002309583A AU 2002309583 A1 AU2002309583 A1 AU 2002309583A1
Authority
AU
Australia
Prior art keywords
methods
lung cancer
modulators
diagnosis
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002309583A
Inventor
Natasha Aziz
Richard Murray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of AU2002309583A1 publication Critical patent/AU2002309583A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002309583A 2001-04-18 2002-04-18 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer Abandoned AU2002309583A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US28477001P 2001-04-18 2001-04-18
US60/284,770 2001-04-18
US29049201P 2001-05-10 2001-05-10
US60/290,492 2001-05-10
US33924501P 2001-11-09 2001-11-09
US60/339,245 2001-11-09
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US33437001P 2001-11-29 2001-11-29
US60/334,370 2001-11-29
US37224602P 2002-04-12 2002-04-12
US60/372,246 2002-04-12
PCT/US2002/012476 WO2002086443A2 (en) 2001-04-18 2002-04-18 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer

Publications (1)

Publication Number Publication Date
AU2002309583A1 true AU2002309583A1 (en) 2002-11-05

Family

ID=27559574

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002309583A Abandoned AU2002309583A1 (en) 2001-04-18 2002-04-18 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer

Country Status (5)

Country Link
EP (1) EP1463928A2 (en)
JP (1) JP2005527180A (en)
AU (1) AU2002309583A1 (en)
CA (1) CA2444691A1 (en)
WO (1) WO2002086443A2 (en)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2709771A1 (en) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US7164009B2 (en) 2000-09-15 2007-01-16 Genentech, Inc. Pro9821 polypeptides
US20030124534A1 (en) 2000-12-08 2003-07-03 Luca Rastelli Method of detecting and treating Tuberous Sclerosis Complex associated disorders
US20060035237A1 (en) * 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
WO2002098356A2 (en) * 2001-06-05 2002-12-12 Exelixis Inc. Ppp2cs as modifiers of the p53 pathway and methods of use
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
CA2470088A1 (en) * 2001-12-20 2003-07-03 Tularik Inc. Identification of an amplified gene and target for drug intervention
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
DE10225144A1 (en) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh Tumor-associated peptides binding to MHC molecules
EP1552845A4 (en) * 2002-06-26 2006-06-07 Takeda Pharmaceutical Preventives/remedies for cancer
GB0215224D0 (en) * 2002-07-01 2002-08-14 Inpharmatica Ltd Protein
US7803370B2 (en) 2002-08-30 2010-09-28 Oncotherapy Science, Inc. Method for treating synovial sarcoma
AU2003256079A1 (en) * 2002-08-30 2004-03-19 Japan As Represented By President Of The University Of Tokyo Method for treating synovial sarcoma
JP2005537810A (en) * 2002-09-11 2005-12-15 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060134622A1 (en) * 2002-12-20 2006-06-22 Meena Augustus Amplified cancer target genes useful in diagnosis and thereapeutic screening
AU2003292737A1 (en) * 2002-12-24 2004-07-22 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
EP1577322A4 (en) * 2002-12-26 2006-01-25 Takeda Pharmaceutical Novel proteins and use thereof
EP1599606A1 (en) * 2003-03-03 2005-11-30 Arizona Board of Regents on behalf of The University of Arizona Protein tyrosine phosphatase - prl-1 a a marker and therapeutic target for pancreatic cancer
NZ542490A (en) * 2003-03-11 2008-04-30 Univ British Columbia Diagnosis of gynecological neoplasms by detecting the levels of oviduct-specific glycoprotein
AU2004224448A1 (en) * 2003-03-24 2004-10-07 Corixa Corporation Detection and monitoring of lung cancer
AU2003901511A0 (en) * 2003-03-28 2003-04-17 Bionomics Limited Nucleic acid molecules associated with angiogenesis II
EP1619499B1 (en) 2003-04-25 2011-01-05 Takeda Pharmaceutical Company Limited Novel screening method
WO2004097034A2 (en) * 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 4 (tmprss4)
WO2004111197A2 (en) * 2003-06-10 2004-12-23 Trustees Of Boston University Gene expression signatures, methods and compositions for diagnosing disorders of the lung
EP2327796A1 (en) * 2003-06-10 2011-06-01 The Trustees Of Boston University Detection methods for disorders of the lung
WO2005002417A2 (en) * 2003-06-20 2005-01-13 Avalon Pharmaceuticals, Inc. Cancer -linked gene aas target for chemotherapy
CN1867679B (en) * 2003-07-17 2012-10-03 环太平洋生物技术有限公司 Markers for detection of gastric cancer
ES2579836T3 (en) 2003-11-06 2016-08-17 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation with ligands
AU2004298604B2 (en) * 2003-12-15 2010-09-23 The Regents Of The University Of California Molecular signature of the PTEN tumor suppressor
JP2008507261A (en) * 2004-01-27 2008-03-13 コンピュゲン ユーエスエイ，インク． Novel nucleotide and amino acid sequences for lung cancer diagnosis, and assays and methods of use thereof
JP2005230011A (en) * 2004-02-20 2005-09-02 Samsung Electronics Co Ltd Mammary cancer related protein, gene coding the same, and mammary cancer diagnostic method using the protein or the gene
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US7399469B2 (en) * 2004-03-26 2008-07-15 Pdl Biopharma, Inc. Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
JP2005314397A (en) * 2004-03-31 2005-11-10 Mitsubishi Chemicals Corp Anti-chondromodulin-1-specific antibody and its use
EP1743944A4 (en) 2004-04-23 2011-01-05 Takeda Pharmaceutical Novel method of screening
DE102004023187A1 (en) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
DE602005020786D1 (en) 2004-06-03 2010-06-02 Takeda Pharmaceutical NEW PROTEIN COMPLEX AND APPLICATIONS THEREOF
CA2579558A1 (en) * 2004-09-08 2006-03-16 Ludwig Institute For Cancer Research Cancer-testis antigens
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US8034578B2 (en) * 2004-10-19 2011-10-11 Oncotherapy Science, Inc. PKP3 oncogene as a prognostic indicator for lung cancer
EP1846550A2 (en) * 2005-02-10 2007-10-24 Centre National De La Recherche Scientifique (Cnrs) Use of the mcm8 gene for the preparation of a pharmaceutical composition
ES2459466T3 (en) 2005-02-25 2014-05-09 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
DE102005013846A1 (en) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
WO2006113467A2 (en) 2005-04-14 2006-10-26 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
ATE525401T1 (en) * 2005-05-13 2011-10-15 Oxford Biomedica Ltd MHC CLASS I AND II PEPTIDE ANTIGENS DERIVED FROM TUMOR ANTIGEN 5T4
PT1957539E (en) 2005-12-08 2013-06-25 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use
GB0526498D0 (en) * 2005-12-28 2006-02-08 Randox Lab Ltd Method
AU2007223788B2 (en) 2006-03-09 2012-11-29 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
HUE025989T2 (en) 2006-03-21 2016-05-30 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
JP5298266B2 (en) * 2006-03-31 2013-09-25 静岡県 Evaluation kit for small cell lung cancer
JP5114637B2 (en) * 2006-03-31 2013-01-09 静岡県 Determination method of small cell lung cancer
KR101351208B1 (en) 2006-06-21 2014-01-14 온코세라피 사이언스 가부시키가이샤 Tumor-targeting monoclonal antibodies to fzd10 and uses thereof
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
EP2050466B1 (en) 2006-08-14 2015-10-28 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
EP1932854A1 (en) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lysosomal associated membrane protein (LAMP) - like polypeptide, ligands to the same, and use of the same in the frame of detection and purification of human plasmacytoid dendritic cells
TWI596109B (en) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 Peptide vaccines for cancers expressing tumor-associated antigens
AU2008251877A1 (en) 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
CA2688299A1 (en) * 2007-05-29 2008-12-18 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
SI2182981T1 (en) 2007-08-02 2013-05-31 Gilead Biologics, Inc. Methods and compositions for treatment and diagnosis of fibrosis
RU2483078C2 (en) 2007-08-20 2013-05-27 Онкотерапи Сайенс, Инк. Cdh3-peptide and drug preparation containing it
CA2697517A1 (en) * 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Cancer-related genes, cdca5, epha7, stk31 and wdhd1
AU2008296927C1 (en) * 2007-09-06 2015-08-13 Case Western Reserve University Methods for diagnosing and treating cancers
AU2008302076B2 (en) 2007-09-19 2015-06-11 The Trustees Of Boston University Identification of novel pathways for drug development for lung disease
AR066170A1 (en) 2007-09-26 2009-07-29 Genentech Inc ANTI INTEGRINA ALFA 5 BETA 1
ES2532635T3 (en) 2008-07-15 2015-03-30 Genentech, Inc. Anthracycline conjugates, process for its preparation and its use as antitumor compounds
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
MX2011002322A (en) * 2008-09-09 2011-05-10 Somalogic Inc Lung cancer biomarkers and uses thereof.
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
EP2342334A4 (en) 2008-09-29 2012-03-14 Univ Pennsylvania Tumor vascular marker-targeted vaccines
SG195571A1 (en) 2008-10-22 2013-12-30 Oncotherapy Science Inc Rab6kifl/kif20a epitope peptide and vaccines containing the same
JP2012506236A (en) * 2008-10-24 2012-03-15 オンコセラピー・サイエンス株式会社 Screening method for anti-lung cancer compound or anti-esophageal cancer compound
CA3050455A1 (en) 2008-11-03 2010-06-03 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
WO2010095461A1 (en) * 2009-02-20 2010-08-26 国立大学法人東京大学 Novel monoclonal antibody, and use thereof
JP6051048B2 (en) 2009-03-25 2016-12-21 ジェネンテック， インコーポレイテッド Novel anti-α5β1 antibody and use thereof
EP2427575B1 (en) 2009-05-07 2018-01-24 Veracyte, Inc. Methods for diagnosis of thyroid conditions
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
CA2771702A1 (en) 2009-08-21 2011-02-24 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and loxl2
JP2013504585A (en) 2009-09-09 2013-02-07 セントローズ， エルエルシー Extracellular targeted drug complex
WO2011051271A2 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Prostate tumor markers and methods of use thereof
US10288617B2 (en) 2009-10-26 2019-05-14 Externautics Spa Ovary tumor markers and methods of use thereof
US20120322075A1 (en) * 2009-10-26 2012-12-20 Externautics S.P.A. Lung Tumor Markers and Methods of Use Thereof
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
MX2012011901A (en) 2010-04-15 2012-11-29 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof.
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5905003B2 (en) * 2010-07-09 2016-04-20 ソマロジック・インコーポレーテッド Lung cancer biomarkers and their use
SG2014007454A (en) 2010-08-13 2014-07-30 Somalogic Inc Pancreatic cancer biomarkers and uses thereof
LT2621526T (en) 2010-09-29 2018-09-25 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
CN103313990B (en) 2010-11-17 2016-07-20 基因泰克公司 Alanyl maytansinol antibody coupling matter
RS59080B1 (en) 2011-03-31 2019-09-30 Adc Therapeutics Sa Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
MX350152B (en) 2011-10-14 2017-08-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof.
PL2802351T3 (en) 2012-01-09 2019-11-29 Adc Therapeutics Sa Agents for treating triple negative breast cancer
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
CA2887897C (en) 2012-10-12 2020-02-18 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd25 antibody conjugates
PL2839860T3 (en) 2012-10-12 2019-10-31 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
HUE035694T2 (en) 2012-10-12 2018-05-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN105246894A (en) 2012-12-21 2016-01-13 斯皮罗根有限公司 Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CA2904044C (en) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
SG11201507214SA (en) 2013-03-13 2015-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
BR112015023333A8 (en) 2013-03-13 2018-04-17 Medimmune Ltd pyrrolbenzodiazepines and conjugates thereof
EP2968988A4 (en) 2013-03-14 2016-11-16 Allegro Diagnostics Corp Methods for evaluating copd status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
MX2016001862A (en) 2013-08-12 2016-08-03 Genentech Inc 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
MX2016007578A (en) 2013-12-16 2016-10-03 Genentech Inc 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
CR20160271A (en) 2013-12-16 2016-12-02 Genentech Inc PEPTIDOMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES
EP3082874A2 (en) 2013-12-16 2016-10-26 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
JP6531166B2 (en) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugate
BR112017003236A2 (en) 2014-09-12 2017-11-28 Genentech Inc cysteine engineered antibodies, drug conjugates and antibodies, drug and antibody conjugate preparation method and pharmaceutical composition
CN106714844B (en) 2014-09-12 2022-08-05 基因泰克公司 Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
AU2015317653A1 (en) 2014-09-17 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
CN107148285B (en) 2014-11-25 2022-01-04 Adc治疗股份有限公司 Pyrrolobenzodiazepine-antibody conjugates
MX2017007169A (en) 2014-12-03 2018-05-02 Genentech Inc Quaternary amine compounds and antibody-drug conjugates thereof.
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
PL3388075T3 (en) 2015-03-27 2023-12-11 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors (seq id 25 - mrax5-003)
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
EP3433621A1 (en) 2016-03-25 2019-01-30 H. Hoffnabb-La Roche Ag Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
CN109689111B (en) 2016-08-11 2024-04-05 基因泰克公司 Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN110139674B (en) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 Method for preparing antibody drug conjugates
TWI762516B (en) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 Monoclonal antibodies against FZD10 and their uses
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TW201839136A (en) 2017-02-06 2018-11-01 瑞士商諾華公司 Compositions and methods for the treatment of hemoglobinopathies
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
DK3544636T3 (en) 2017-02-08 2021-05-10 Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates
DK3612537T3 (en) 2017-04-18 2022-08-08 Medimmune Ltd PYRROLOBENZODIAZEPIN CONJUGATES
PL3612234T3 (en) 2017-04-20 2024-09-02 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
EP3638373B1 (en) 2017-06-14 2024-09-04 ADC Therapeutics SA Dosage regimes for the administration of an anti-cd19 adc
ES2906965T3 (en) 2017-08-18 2022-04-21 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EP3684773A1 (en) 2017-09-20 2020-07-29 pH Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
CN113227119A (en) 2018-12-10 2021-08-06 基因泰克公司 Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN114163510A (en) * 2021-03-24 2022-03-11 深圳市新靶向生物科技有限公司 Antigenic peptide combination related to liver cancer driver gene mutation and application thereof
EP4294951A1 (en) * 2022-05-13 2023-12-27 Hummingbird Diagnostics GmbH Novel rna molecule for cancer detection
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof

Also Published As

Publication number Publication date
JP2005527180A (en) 2005-09-15
WO2002086443A8 (en) 2004-06-17
WO2002086443A2 (en) 2002-10-31
CA2444691A1 (en) 2002-10-31
EP1463928A2 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU2002330039A1 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU2002347428A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2002252144A1 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
WO2002079492A8 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2002215345A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002339865A1 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
AU2001261007A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002311909A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
AU2002218770A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003022987A9 (en) Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
AU2002254482A1 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
AU2001290902A1 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
AU3755300A (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2002359330A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002364708A1 (en) Novel compositions and methods for cancer
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase